SCHEMBL4098216

SCHEMBL4098216

O=C(O)/C=C/C=C(\c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.53
CES1 P23141 2/20 0.53
CYP1B1 Q16678 1/20 0.47
MAOB P27338 1/20 0.47
MAPT P10636 4/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
PTGS2 P35354 1/20 0.43
PTAFR P25105 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
NR4A1 P22736 1/20 0.42
PDPK1 O15530 1/20 0.42
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4098220 1.00 CES2 (0.53) CES2CES1CYP1B1MAOBMAPT
SCHEMBL4098224 1.00 CES2 (0.53) CES2CES1CYP1B1MAOBMAPT
SCHEMBL3945842 0.95 ALOX15 (0.48) CES2CES1CYP1B1MAOBMAPT
SCHEMBL3945845 0.95 ALOX15 (0.48) CES2CES1CYP1B1MAOBMAPT
SCHEMBL10399085 0.95 ALOX15 (0.48) CES2CES1CYP1B1MAOBMAPT
SCHEMBL1232561 0.89 HDAC3 (0.45) CES2CES1CYP1B1MAOBMAPT
SCHEMBL10399188 0.89 HDAC3 (0.45) CES2CES1CYP1B1MAOBMAPT
SCHEMBL3943435 0.89 HDAC3 (0.45) CES2CES1CYP1B1MAOBMAPT
SCHEMBL3949027 0.83 NR4A1 (0.45) CES2CES1CYP1B1MAOBNR4A1
SCHEMBL3949030 0.83 NR4A1 (0.45) CES2CES1CYP1B1MAOBNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 CES2 3693/4885CES1 2445/4885CYP1B1 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.